The clinical rationale for expanding access is grounded in shifting epidemiology. Hepatocellular carcinoma, the most common primary liver cancer, has risen substantially in incidence and mortality in the United States and worldwide, increasingly driven by non-viral causes such as metabolic-dysfunction-associated steatotic liver disease, or MASLD. Current American Association for the Study of Liver Diseases guidelines do not recommend routine surveillance for most MASLD patients unless they develop cirrhosis, which means many tumors are caught at later stages. With roughly two-thirds of patients falling into the intermediate or advanced categories of the Barcelona Clinic Liver Cancer staging system, where liver-directed therapies play a central and evolving role, the authors contend that improved access to these treatments is essential to meet a growing healthcare burden.

Radioembolization works by threading millions of microscopic beads loaded with yttrium-90, a beta-emitting radionuclide, through the hepatic artery directly into the vessels feeding a tumor. The radiation travels an average of only a few millimeters in tissue, delivering tumoricidal doses while sparing much of the surrounding liver. Over the past two decades the technique has moved from lobar, body-surface-area-based dosing toward superselective, segmental delivery guided by personalized dosimetry. That shift has transformed its role. Radiation segmentectomy, in which an ablative dose is concentrated in one or two liver segments, has created a curative-intent option for selected patients with early-stage disease who are not ideal candidates for surgery or thermal ablation.

The evidence supporting this evolution is now substantial. Early randomized trials comparing radioembolization with the drug sorafenib, including SARAH and SIRveNIB, showed no overall survival advantage, but those studies predate modern patient selection and dosimetry. A post hoc analysis of SARAH found that patients receiving adequate tumor absorbed dose derived greater benefit, pointing directly at dosimetry as the missing variable. The randomized DOSISPHERE-01 trial then demonstrated improved objective response rates and overall survival when dosing was personalized to maximize tumor absorbed dose compared with standard approaches. Studies such as LEGACY, RASER, and DOORwaY90 have since shown high response rates with segmental high-dose delivery, and comparative trials including TRACE and PREMIERE suggest potential advantages over chemoembolization in selected patients, including longer time to progression and fewer treatment sessions.

In the transplant arena, radioembolization has become the most commonly used liver-directed therapy in the United States for bridging and downstaging patients awaiting a new liver. A key metric is complete pathologic necrosis, the disappearance of viable tumor on examination of the explanted liver, which radioembolization achieves at consistently high rates compared with other locoregional therapies and which is associated with better post-transplant outcomes. Emerging data suggest, however, that factors beyond mean tumor dose, such as microsphere-specific activity, particle density, and spatial dose heterogeneity, may independently influence the radiobiologic effect. Because glass and resin microspheres differ substantially in these properties, the authors caution that dose targets and delivery strategies may not be interchangeable across platforms, and future guidelines should account for microsphere type, treated vascular territory, and the intended biologic endpoint.

Regulatory milestones have accelerated adoption. The U.S. Food and Drug Administration granted premarket approval for TheraSphere glass microspheres for unresectable hepatocellular carcinoma in March 2021, while SIR-Spheres resin microspheres, approved in 2002 for colorectal liver metastases, received an added unresectable HCC indication in 2025. Unified practice parameters, including the 2023 ACR-ABS-ACNM-ARS-SIR-SNMMI practice parameter, have standardized patient selection, lung shunt assessment, dose planning, and radiation safety, making results more reproducible across centers. But standardization also raises the bar: a credible program now requires reliable nuclear medicine collaboration, dosimetry support, trained interventional radiology staff, consistent imaging protocols, and a system for tracking outcomes.

The operational heart of the review is a detailed team structure. Interventional radiologists lead protocol development, case selection, dosimetry oversight, and informed consent, supported by nurses, technologists, and advanced practice providers. Medical physicists implement and audit dosimetric protocols; nuclear medicine physicians and radiopharmacists manage the radiotracer and interpret lung shunt and post-therapy imaging; and hepatology, oncology, transplant surgery, diagnostic radiology, and palliative care contribute through a multidisciplinary tumor board. A standardized pathway converts this structure into reproducible care, moving patients from referral intake through tumor board presentation, interventional radiology clinic visits, mapping angiography with technetium-99m MAA imaging, dosimetric review, treatment, and structured follow-up. Quality is monitored with pragmatic metrics: process measures such as time from referral to treatment and a work-up completion rate above 90 percent as an aspirational benchmark, clinical measures such as response rates and downstaging success, and safety measures tracking unplanned admissions, gastrointestinal ulceration, radiation pneumonitis, and deterioration in liver function within 90 days.

A recurring theme is the central role of the dedicated nurse coordinator, who serves as the program’s operational and clinical liaison. Within the boundaries of nursing scope of practice, the coordinator navigates patients through the pathway, prepares families for the logistics of separate mapping and treatment visits, coordinates authorizations and appointments across services, and conducts structured post-procedure check-ins to catch symptoms early. The authors emphasize that this role often becomes the most continuous point of contact for patients and families, providing emotional support and a trusted space for questions throughout a protracted treatment journey. Patient decision aids, including bilingual tools developed by the Interventional Initiative, have been shown in clinical trials to improve understanding and satisfaction before informed consent conversations.

The review also confronts the business case frankly. Hospitals that refer radioembolization cases out lose revenue from the entire episode of care, including imaging, clinic visits, mapping procedures, nuclear medicine studies, and follow-up. A make-versus-buy analysis must weigh fixed assets such as angiography suites and dosimetry software against variable costs and projected volume; a program may be profitable per case yet unjustifiable at very low volume near a high-quality regional center. Conversely, rural or geographically isolated hospitals may justify an in-house program even at lower volume if local treatment reduces travel burden and shortens time to therapy, considerations that carry particular weight for nonprofit and government systems. The authors propose a three-phase implementation timeline: stakeholder engagement, protocol development, and device-specific training; treatment of an initial cohort of straightforward cases with real-time dashboards tracking patient flow; and early outcomes review culminating in an internal playbook that consolidates workflows and supports onboarding and growth.

Ultimately, the authors argue that a high-performing radioembolization practice is best understood as a service line rather than a procedure. Durable, reproducible outcomes require an intentional infrastructure linking multidisciplinary decision-making, evidence-based selection, personalized dosimetry, nuclear medicine partnership, trained procedural teams, coordinated nursing navigation, and longitudinal outcome tracking. When leadership support, patient-centered education, and continuous process improvement are deliberately built in, the therapy can expand access to advanced liver-directed treatment, reduce fragmentation of care, and strengthen the broader hepatobiliary oncology ecosystem. The future of radioembolization, they conclude, depends not only on better devices, dosimetry, and trials, but on building systems capable of delivering the therapy safely, consistently, and in alignment with patient goals.

Subject of Research: Building and sustaining high-performing yttrium-90 radioembolization programs for liver cancer

Article Title: Building a high-performing yttrium-90 radioembolization practice: from evidence to experience

Article References: Malone, C., Friend, C., Schmitt, B., Siskin, G., & Newton, I. (2026). Building a high-performing yttrium-90 radioembolization practice: from evidence to experience. CVIR Oncology, 2(1), Article 30. https://doi.org/10.1007/s44343-026-00064-0

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00064-0

Keywords: yttrium-90, radioembolization, hepatocellular carcinoma, radiation segmentectomy, personalized dosimetry, liver-directed therapy, interventional radiology, nuclear medicine, transplant bridging, multidisciplinary care, nurse coordinator, program development

The study, published in CVIR Oncology, draws on the CIRT registry spanning 27 sites across eight European countries and its French counterpart, CIRT-FR, which was conducted to help the French Health Authority evaluate reimbursement of yttrium-90 resin microspheres. Both registries were designed to capture real-world clinical practice rather than the tightly scripted conditions of a randomized trial, and that realism is precisely what makes the findings interesting. Physicians recorded their planned treatment intent at the start of therapy, but the researchers later reclassified each patient’s actual trajectory using predefined criteria covering transplantation, ablation, resection, or a sustained complete response lasting at least one year as measured by modified RECIST criteria.

The headline numbers tell a story about the gap between intention and outcome. Although 229 of the 615 patients, roughly 37 percent, were initially slated for curative-intent treatment pathways, only 40 patients, or 6.5 percent, ultimately met the retrospective curative-intent definition, while 93 percent were classified as palliative. Of those 40, half went on to liver transplantation after TARE, seven received ablation and two underwent resection. Most remarkably, 11 patients, 27.5 percent of the curative group, required no further treatment at all because TARE alone had produced a complete tumor response documented for at least a year.

That last figure carries particular weight given how the authors framed their expectations. Among 32 patients whose a priori plan was radiation segmentectomy, meaning planned curative yttrium-90 monotherapy, only one ultimately achieved a curative classification through subsequent transplantation. In other words, the patients who ended up cured by radiation alone were rarely the ones selected for that purpose in advance. Their complete responses were, in a sense, discovered rather than engineered, which the authors say underscores how little consensus currently exists on who will convert to a curative pathway after radioembolization and how urgently refined conversion criteria are needed.

The statistical analysis offers some clues. In multivariable logistic regression, three factors independently predicted placement in the curative-intent group: an ECOG performance status of zero, corresponding to fully active patients, carried an odds ratio of 0.44; having one to three tumors yielded an odds ratio of 0.39; and a total tumor volume below 150 cubic centimeters produced an odds ratio of 0.40. That 150 cubic centimeter threshold emerged from receiver operating characteristic analysis as one of two optimal cut points for separating curative from palliative patients, and it was selected for its higher specificity of 0.725. Notably, 72.5 percent of curatively treated patients fell below this volume, which is substantially larger than the roughly 65 cubic centimeter ceiling imposed by the classic Milan criteria for transplantation eligibility.

This discrepancy is central to the paper’s argument. The Milan criteria, which have governed transplant selection for hepatocellular carcinoma for nearly three decades, rest almost entirely on morphometric measurements, and the authors found no significant differences between their curative and palliative groups on Milan-based eligibility before treatment. Around 80 percent of the curatively managed patients were outside Milan criteria before TARE. The implication is that radioembolization can shrink tumors enough to pull patients back within transplant boundaries, and that tumor volume thresholds well beyond Milan’s limits, combined with biological markers such as alpha-fetoprotein and the ALBI grade of liver function, may better identify who stands to benefit. The authors point to emerging tools like the Metroticket 2.0 model as the kind of finer-grained metrics the field needs.

Dosimetry adds another technical layer to the story. Because absorbed radiation doses were not prospectively collected in the original registries, the team recalculated them retrospectively using the simplified Medical Internal Radiation Dose formula, dividing administered activity by tumor mass. Their surrogate analysis found that absorbed doses above 400 grays correlated with longer survival, a threshold repeatedly associated with complete response in prior literature. Crucially, 92.3 percent of patients who received doses above that level had tumors under 150 cubic centimeters, suggesting that the concentration of radiation achievable in smaller, more selectively targeted volumes is what drives these dramatic responses. Yet the data also showed that doses exceeding 400 grays remained effective in tumors up to about 150 cubic centimeters, roughly 6.6 centimeters in diameter, larger than many earlier studies had considered treatable at such intensities.

Survival outcomes reinforce the signal. Median overall survival was not reached in the complete response, resection, and ablation subgroups by the end of follow-up, and in the transplantation subgroup, 75 percent and 85 percent survival percentiles were reached at 37.1 and 11.4 months respectively, with only one death recorded in the resection and ablation group and none in the complete response group. By contrast, the palliative group’s median survival of 16.1 months compares favorably with the 8.0 and 8.8 months reported in the landmark SARAH and SIRveNIB randomized trials of radioembolization versus sorafenib in advanced disease, and aligns with more recent prospective figures of 13.9 months. The real-world palliative performance alone is notable, but the theoretical cure fractions achieved in a minority of patients are what will spark debate.

The authors are careful about the limits of their evidence. This was an exploratory, retrospective classification layered onto prospective observational data, with no harmonized definition of curative intent when the studies began. Baseline characteristics were collected only before TARE, alpha-fetoprotein levels were missing in more than a fifth of curative patients and more than 40 percent of palliative patients, and dosimetry relied on a surrogate calculation. The heterogeneity of post-TARE curative procedures across different national practices further complicates generalization. Still, the conclusion is clear and consequential: yttrium-90 radioembolization belongs not just in the palliative toolbox but across the full spectrum of curative-intent strategies for hepatocellular carcinoma, whether as a bridge to transplantation, a downstaging tool before resection or ablation, or, in carefully selected patients with small tumor burdens and good performance status, as a standalone therapy capable of eradicating the disease outright. The task now facing the field, the authors argue, is to marry morphometry, tumor biology, and personalized dosimetry into reliable criteria that can identify, before the first microsphere is injected, which patients will be among the lucky few whose cancer never returns.

Subject of Research: Curative-intent transarterial radioembolization with yttrium-90 in hepatocellular carcinoma

Article Title: Hepatocellular carcinoma patients treated with TARE monotherapy or combination therapy with curative intent: a retrospective, exploratory analysis of two European prospective studies

Article References: Helmberger, T., Arnold, D., Loffroy, R., Ronot, M., Sangro, B., Kolligs, F., Pellerin, O., Maleux, G., Peynircioglu, B., Schaefer, N., Bilbao, J. I., de Jong, N., Geyer, M., Zeka, B., Urdaniz, M., & Vilgrain, V. (2026). Hepatocellular carcinoma patients treated with TARE monotherapy or combination therapy with curative intent: a retrospective, exploratory analysis of two European prospective studies. CVIR Oncology, 2(1), Article 5. https://doi.org/10.1007/s44343-026-00035-5

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00035-5

Keywords: hepatocellular carcinoma, TARE, yttrium-90, radioembolization, liver transplantation, radiation segmentectomy, Milan criteria, dosimetry, tumor downstaging, locoregional therapy, complete response, CIRT registry

The study, published in CVIR Oncology, analyzed data from the CIRSE Registry for SIR-Spheres Therapy, known as CIRT, a Europe-wide observational study conducted in eight countries across 27 centers. Of the 1,036 patients enrolled with primary or secondary liver malignancies, the researchers focused on 169 adults whose liver metastases originated from neuroendocrine tumors, breast cancer, pancreatic cancer, or melanoma. All were treated with yttrium-90 resin microspheres, tiny radioactive spheres delivered through the hepatic artery that lodge in the small vessels feeding tumors and deliver high-dose internal radiation while sparing most healthy tissue.

The technical logic behind TARE is elegant. Unlike conventional external beam radiotherapy, which must pass through healthy tissue to reach its target, radioembolization exploits the fact that liver tumors draw their blood supply predominantly from the hepatic artery, while healthy liver tissue depends on the portal vein. Catheters threaded from a puncture in the groin or wrist guide the microspheres into the arteries supplying the tumors, where the beta radiation from yttrium-90, which travels only a few millimeters in tissue, kills cancer cells from within. Before treatment, teams perform careful mapping angiography and dosimetry, often using the body surface area method or a partition model, to calculate the activity to be injected and to avoid reflux of spheres into the stomach or bowel.

The survival results varied dramatically by tumor type, underscoring how different these diseases are. Patients with neuroendocrine tumors fared best, with a median overall survival of 33.3 months after treatment. Those with breast cancer liver metastases had a median survival of 10.7 months, while patients with melanoma reached 14.7 months. Pancreatic cancer, notoriously aggressive even when it has spread only to the liver, showed the poorest outcome at 5.6 months. Median follow-up ranged from 5.6 months in the pancreatic cohort to 19.3 months in the neuroendocrine group, and patients were enrolled between January 2015 and December 2017 with follow-up through the end of 2019.

Safety was the study’s most consistent message. Severe adverse events of grade three or higher, defined according to the standard CTCAE criteria, occurred in just 10 percent of all 169 patients. Procedure-related adverse events were predominantly mild to moderate, affecting roughly one in five neuroendocrine and breast cancer patients and only about six percent of those with pancreatic cancer or melanoma. Predefined serious events tracked in the registry included abdominal pain, fatigue, fever, nausea, vomiting, gastrointestinal ulceration, gastritis, and radiation cholecystitis, but these remained uncommon. For a therapy that delivers ionizing radiation directly into a vital organ, this safety profile across four very different tumor types is a notable result.

Perhaps the most scientifically intriguing findings came from the multivariable analysis, in which the researchers used Cox proportional hazards models to identify independent predictors of survival. Two laboratory-based markers emerged repeatedly. The Albumin-Bilirubin grade, or ALBI, which combines liver synthetic function with bile clearance, predicted worse overall survival in both the neuroendocrine and breast cancer cohorts, with hazard ratios above four. The Aspartate transaminase to Platelet Ratio Index, or APRI, a marker usually associated with liver fibrosis, predicted poorer survival in the neuroendocrine and melanoma cohorts. In melanoma patients the effect was striking: an APRI value above 0.40 carried a hazard ratio of 37.63 for death, an extraordinarily strong association. In breast cancer patients, an international normalized ratio above one and an elevated neutrophil-to-leukocyte ratio also predicted worse progression-free survival.

These biomarker findings carry practical weight. They suggest that the health of the underlying liver, and possibly the systemic inflammatory state reflected in blood counts, shapes how much patients benefit from internal radiation, and that the relevant markers differ by tumor type. The authors argue this supports individualized patient assessment that incorporates both the histology of the metastases and routine laboratory evaluation. It also hints that simple blood tests available before treatment could help clinicians select which patients are most likely to benefit, an increasingly important question as liver-directed therapies proliferate.

Context matters for interpreting the survival numbers. For neuroendocrine liver metastases, which develop in up to 80 percent of patients with these tumors, the 33.3 month median survival aligns closely with a systematic review of 809 patients that reported a pooled overall survival of 33 months, and with the American RESiN registry, which reported a median of 33 months. For breast cancer, the 10.7 month result is comparable to a meta-analysis of 452 patients that found a median of 11.3 months. In melanoma, where nearly 60 percent of the study’s patients received TARE as first-line liver-directed therapy, the 14.7 month median sits comfortably within the 9 to 24 month range reported across systematic reviews of radioembolization for uveal melanoma. The pancreatic cancer result, while bleak, reflects a disease in which even surgery and modern chemotherapy yield median survivals under a year in the metastatic liver setting.

The study’s authors are careful about its limits. As an observational registry without a control group, it cannot prove that TARE is superior to other options, and selection bias and residual confounding cannot be excluded. The lack of a standardized treatment protocol across 27 centers introduced heterogeneity in baseline characteristics, treatment timing, and surrounding systemic therapies. Missing data may have affected some analyses, and no multivariable model was possible for the pancreatic cohort because too few variables reached the significance threshold. What the study does provide is something rarer: prospectively collected, multicenter, real-world evidence about how TARE is actually used and how patients actually fare when multidisciplinary teams choose it for tumors that fall outside existing guidelines.

That guideline gap is precisely why the results matter. TARE is a standard of care for intermediate to advanced hepatocellular carcinoma and for metastatic colorectal cancer, but for non-colorectal liver metastases, formal recommendations have been largely absent; the European Neuroendocrine Tumour Society recently noted that no data existed on liver embolization for neuroendocrine carcinoma. By documenting safety and encouraging effectiveness in 169 patients across four tumor types, the CIRT analysis gives clinicians a firmer evidence footing for a treatment many were already offering, and it sets a clear agenda: prospective comparative studies are now needed to identify which patient groups benefit most, and simple markers like ALBI and APRI may help decide who should be offered the radioactive beads and who should be spared the procedure.

Subject of Research: Yttrium-90 transarterial radioembolization for non-colorectal liver metastases

Article Title: Transarterial radioembolization for liver metastases of non-colorectal origin: safety and effectiveness results from the prospective multicenter CIRSE registry for SIR-spheres therapy (CIRT)

Article References: Arnold, D., Chlorogiannis, D. D., Sangro, B., Kolligs, F., Maleux, G., Bilbao, J. I., Pech, M., Pfammatter, T., de Jong, N., Geyer, M., Urdániz, M., & Helmberger, T. (2026). Transarterial radioembolization for liver metastases of non-colorectal origin: safety and effectiveness results from the prospective multicenter CIRSE registry for SIR-spheres therapy (CIRT). CVIR Oncology, 2(1), Article 6. https://doi.org/10.1007/s44343-026-00039-1

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00039-1

Keywords: transarterial radioembolization, yttrium-90, liver metastases, neuroendocrine tumors, breast cancer, pancreatic cancer, melanoma, SIR-Spheres, CIRT registry, ALBI grade, APRI, interventional radiology

TARE has become a mainstay of modern liver cancer care because of its unusual elegance. Rather than flooding the whole body with chemotherapy, clinicians deliver yttrium-90, a beta-emitting isotope bound to glass or resin microspheres roughly the width of a red blood cell, directly into the arteries that feed the tumor. The spheres lodge in the small vessels surrounding the malignancy and bathe it in high-dose radiation while sparing most healthy tissue. The technique works across the full spectrum of liver cancer severity, from early-stage disease where it can bridge patients to transplant, to advanced stages where it serves primarily to control tumor growth. Its safety record is genuinely impressive: serious adverse events occur in only about nine percent of patients, and vascular injury is estimated at no more than one percent of cases, typically arising when arterial anatomy is unusually complex, vessels have been weakened by prior chemotherapy, or pre-existing vascular abnormalities are present.

The Swiss case began conventionally enough. The patient, a man in his early seventies with liver fibrosis caused by chronic hepatitis C, was found on ultrasound to have a thirty-millimeter lesion in segment VIII of the liver, near the organ’s central hilum where major bile ducts and blood vessels converge. Magnetic resonance imaging and biopsy confirmed a moderately differentiated hepatocellular carcinoma, staged at an early BCLC stage with well-preserved liver function. A multidisciplinary tumor board weighed the options carefully. Percutaneous ablation, usually the first choice for small tumors, was judged too risky because of the lesion’s close proximity to a portal vein branch and the biliary tree. The team instead selected TARE, planning a curative dose of yttrium-90 glass microspheres engineered to deliver an estimated 324 gray to the perfused liver and more than a thousand gray to the tumor itself.

The workup phase went smoothly. Angiography revealed an anatomical quirk, a common hepatic artery arising from the superior mesenteric artery rather than its usual origin, but the team successfully navigated the tortuous route, advanced a microcatheter into the anterior sectoral artery supplying the tumor, and confirmed excellent targeting with technetium-99m-labeled macroaggregated albumin, the standard pre-treatment tracer. Two weeks later, during the therapeutic session, the trouble started. As the microcatheter was advanced along the same vessel, it caused a focal iatrogenic dissection, a tear in the arterial lining that separated the vessel wall into a true lumen and a false channel. Dissections of this kind are a recognized hazard of catheter work; guidelines from the Society of Interventional Radiology suggest they should prevent completion of the intended treatment in fewer than one percent of cases.

The team responded with textbook technique. They swapped the stiffer 2.7 French microcatheter for a softer, more flexible 1.98 French device paired with a fine guidewire, and successfully re-entered the true lumen. Digital subtraction angiography visualized the dissection, but selective intra-arterial CT angiography, a more detailed cross-sectional view taken from inside the vessel, showed no contrast stagnation in the false lumen, no pooling around the catheter tip, and preserved tumor enhancement that looked essentially identical to the simulation phase. Encouraged by these images, the physicians proceeded and administered 2.9 gigabecquerels of yttrium-90. Only afterward did post-treatment positron emission tomography reveal the flaw in that confidence: focal radioactive tracer uptake outside the liver tissue, in the region of the hepatic hilum, exactly where the dissection had occurred. Dosimetry calculations estimated that some 678 gray of radiation, an extraordinary dose by any standard, had pooled on the damaged arterial wall.

The critical insight, one the authors emphasize with some force, is that contrast dye is not a reliable proxy for microsphere behavior. Contrast agents and yttrium-90 spheres differ in particle size, density, and the way they move with blood flow, so a vessel that appears well perfused on angiography can still trap radioactive particles unevenly. In this patient, the dissection created abnormal flow conditions at the hepatic hilum that the intraprocedural imaging could not fully resolve. The spheres that should have been distributed throughout the tumor instead accumulated along an injured arterial wall, setting the stage for a form of collateral damage that is rarely reported and poorly understood: radiation-induced arteritis of the liver’s major vessels.

Because the patient remained symptom-free, he was discharged with daily telephone monitoring and a scheduled CT angiography seven days later, a deliberate precaution given the enormous extraparenchymal dose. That scan proved decisive. It revealed diffuse arteriopathy involving the common, right, and left hepatic arteries and their proximal branches, with multiple wall irregularities and three pseudoaneurysms, the largest measuring seven millimeters in the right hepatic artery. Pseudoaneurysms are balloon-like outpouchings formed when a weakened vessel wall balloons outward under pressure, and their rupture can trigger catastrophic intra-abdominal hemorrhage. The rapid onset of these changes, detectable within a single week, suggested a sinister synergy: mechanical injury from the catheter tearing the intima, compounded almost immediately by yttrium-90 radiation destroying the endothelial cells and muscular media of the vessel wall beneath.

The pathophysiology of radiation-induced vascular injury has been studied mostly in the context of external beam radiotherapy, where it is known to involve endothelial cell death, necrosis of the arterial media, and scarring of the adventitia that progressively narrows vessels or erodes them into aneurysms. Whether the same mechanisms unfold in the intrahepatic circulation after internal radiation has been largely uncharted territory. To the authors’ knowledge, no previous case has documented an iatrogenic arterial dissection during TARE evolving into subacute radiation-associated arteriopathy, which is precisely what makes the report valuable and unsettling. After urgent multidisciplinary consultation and shared decision-making with the patient, the team performed prophylactic coil embolization, deploying a series of detachable and pushable platinum coils through the hepatic arteries to pack shut the abnormal segments. Because the pathology was diffuse and multifocal, a covered stent, which would have preserved the vessel while sealing it, was not feasible, so the physicians accepted permanent sacrifice of the arterial tree. The patient’s preserved Child-Pugh A liver function and compensatory portal venous blood supply made the risk acceptable, though the team openly acknowledged a sobering trade-off: closing these arteries eliminated any possibility of future endovascular treatments if the cancer returned.

The outcome was, by any measure, a success story wrapped around a cautionary tale. Final angiography confirmed complete exclusion of the pseudoaneurysms and abnormal vessels, and transiently elevated liver enzymes normalized within five days. Magnetic resonance imaging at four weeks and three months showed a complete response of the original tumor by RECIST 1.1 criteria, with no biliary injury or hepatic ischemia, and preserved liver function throughout follow-up. A small new lesion in a distant segment was later treated successfully with percutaneous radiofrequency ablation. The authors distill the experience into several key lessons: anticipate vascular injury in patients with complex anatomy, reconsider microsphere delivery whenever arterial dissection occurs, maintain close post-procedural surveillance to catch vascular complications early, and weigh carefully whether definitive arterial embolization forecloses future treatment options. In asymptomatic patients, surveillance alone may suffice, since small pseudoaneurysms can stabilize or resolve, but their natural history is unpredictable and rupture can be lethal, so management must be individualized. For a procedure performed tens of thousands of times each year, this single case is a powerful reminder that even a one-percent risk deserves a protocol, and that the liver’s arteries, once injured and then irradiated, can fail in ways we are only beginning to describe.

Subject of Research: Iatrogenic arterial dissection during transarterial radioembolization leading to radiation-induced hepatic arteritis

Article Title: Iatrogenic arterial dissection leading to radiation induced arteritis following transarterial radioembolization

Article References: Adami, M., Boughdad, S., Villard, N., Schaefer, N., Rafael, D., & Tsoumakidou, G. (2026). Iatrogenic arterial dissection leading to radiation induced arteritis following transarterial radioembolization. CVIR Oncology, 2(1), Article 25. https://doi.org/10.1007/s44343-026-00061-3

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00061-3

Keywords: transarterial radioembolization, hepatocellular carcinoma, yttrium-90, arterial dissection, radiation-induced arteritis, hepatic artery, pseudoaneurysm, coil embolization, interventional radiology, dosimetry, vascular complication, case report

A new single-center retrospective study published in the European Journal of Nuclear Medicine and Molecular Imaging aims to change that. Researchers at Beijing Tsinghua Changgung Hospital analyzed 290 consecutive patients with unresectable hepatocellular carcinoma who underwent yttrium-90 selective internal radiation therapy between October 2022 and December 2025. Among them, 91 were flagged on pre-treatment imaging as potentially receiving tumor blood flow from the inferior phrenic artery, and 78 ultimately had angiographically confirmed supply from that vessel. The team then compared the two main ways interventional radiologists handle the artery: threading microspheres directly through it into the tumor, or deliberately plugging it with coils so that tumor blood flow is redirected back into the liver’s own arterial network.

The technical foundation of the study lies in meticulous pre-procedural mapping. Every patient underwent hepatic digital subtraction angiography combined with cone-beam computed tomography, a pairing that allows physicians to see not just the two-dimensional course of the vessels but the full three-dimensional territory each artery perfuses. A technetium-99m macroaggregated albumin injection followed by SPECT/CT simulation calculated the lung shunt fraction, ensuring that too many microspheres would not escape to the lungs, and post-treatment PET/CT verified where the radioactive spheres actually landed. Using a 2.1 French goose-neck microcatheter, the team achieved superselective catheterization of the inferior phrenic artery in 88.6 percent of attempted cases, demonstrating that even this small, tortuous vessel can be reliably accessed when combined angiographic and tomographic guidance is used.

The decision-making algorithm the researchers propose hinges on two variables: the volume of tumor fed by the inferior phrenic artery and the anatomy of any non-target branches that could carry microspheres into dangerous territory. When the artery perfused at least 20 milliliters of tumor and risky branches could be managed, the team favored direct infusion of yttrium-90 microspheres through the vessel, reserving prophylactic coil embolization for high-risk offshoots such as suprarenal, esophageal, pericardial, or pulmonary shunt branches. When the perfused tumor volume fell below 20 milliliters or non-target vessels could not be safely catheterized, the team simply embolized the artery trunk with coils, wagering that intrahepatic arteries would compensate. Forty-five patients landed in the infusion group and 33 in the embolization group, with the infusion cohort predictably carrying heavier tumor burdens and more advanced disease.

The anatomical findings reinforce how distinctive the inferior phrenic artery can be. The right inferior phrenic artery dominated as the parasitic feeding vessel in 89.8 percent of cases, with the left artery accounting for only 7.7 percent and dual supply appearing in 2.5 percent. Most of these arteries originated from the celiac trunk or directly from the abdominal aorta, though a striking 21.8 percent arose from the renal artery. The median radioactivity delivered through the inferior phrenic artery was a modest 0.3 gigabecquerels, yet the dosimetric payoff was substantial: the median tumor-absorbed dose in the infusion group reached 92 Gy, with three-quarters of those patients receiving at least 61 Gy, approaching the 100 to 250 Gy window widely recommended for hepatocellular carcinoma.

Perhaps the most eye-catching result concerns the embolization strategy, which has always rested on an assumption that had never been carefully quantified. If you plug the parasitic artery, does tumor blood flow really reroute to intrahepatic vessels in time to matter? By comparing intra-procedural cone-beam CT with post-treatment PET/CT, the researchers found that approximately 88 percent of the territory originally supplied by the inferior phrenic artery received yttrium-90 microspheres through compensatory intrahepatic pathways, with more than half of lesions achieving complete hemodynamic compensation. Critically, the compensatory rate held steady regardless of tumor size, suggesting that flow redistribution after coil embolization is a robust phenomenon rather than a fortunate accident, and providing quantitative reassurance comparable to the 83.8 percent redistribution rate previously reported with glue embolization.

On efficacy, direct infusion through the inferior phrenic artery consistently outperformed embolization. Using the modified Response Evaluation Criteria in Solid Tumors, the objective response rate in the infusion group climbed from 60.0 percent at one month to 82.3 percent at three months, whereas the embolization group moved from 48.5 percent to 69.7 percent over the same intervals. The gap between the groups widened to 12.6 percentage points by three months, and the complete response rate in the infusion group surged from 17.8 percent to 46.7 percent, an absolute gain of 28.9 percentage points that far outpaced the 21.2 percent rise seen in the embolization cohort. Disease control rates exceeded 93 percent at one month in both groups, underscoring that neither strategy leaves patients behind.

Safety is where lingering fears about extrahepatic radiation have historically been most vocal, and the study directly confronts them. Mean whole-lung absorbed dose was 9.53 Gy, comfortably below the 20 Gy clinical threshold, with no significant differences between groups in lung volume, lung shunt fraction, or lung dose. The overall adverse event rate was 17.8 percent in the infusion group and 9.1 percent in the embolization group, a difference that was not statistically significant, and every reported event was a mild to moderate, reversible thoracic complaint. No severe treatment-related complications occurred in either arm, an outcome the authors attribute to the discipline of combined DSA-CBCT anatomical evaluation paired with prophylactic embolization of non-target branches whenever they were visualized.

The study’s authors are candid about its limits. As a single-center retrospective analysis, it carries inherent selection bias, and the infusion group’s higher tumor burden and greater proportion of Barcelona Clinic Liver Cancer stage C patients may confound the efficacy comparison. Only three-month tumor response was assessed, leaving progression-free survival and overall survival unmeasured, and the team calls for long-term follow-up and multicenter prospective validation before the algorithm becomes standard practice. Even so, the work represents the largest head-to-head comparison of inferior phrenic artery strategies in yttrium-90 radioembolization to date, and it delivers something the field has lacked: a concrete, volume-based decision rule. Direct infusion when the artery feeds at least 20 milliliters of tumor and the plumbing cooperates; embolization when it does not. For the roughly one in three hepatocellular carcinoma patients whose tumors recruit this diaphragmatic artery, that clarity could mean the difference between an incomplete treatment and a truly definitive one.

Subject of Research: Inferior phrenic artery management strategies during yttrium-90 selective internal radiation therapy for hepatocellular carcinoma.

Article Title: Interventional strategies for inferior phrenic artery management in yttrium‑90 selective internal radiation therapy for hepatocellular carcinoma: A single‑center retrospective study

Article References: Liao, Y., Huang, X., Liang, Z., Ma, J., Feng, X., Fu, W., Liang, B., Yang, S., Li, G., Bao, L., Zhang, T., Zheng, L., Liu, C., Tang, M., Zhang, L., & Dong, J. (2026). Interventional strategies for inferior phrenic artery management in yttrium‑90 selective internal radiation therapy for hepatocellular carcinoma: A single‑center retrospective study. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-026-08170-0

Image Credits: AI Generated

DOI: 10.1007/s00259-026-08170-0

Keywords: yttrium-90, selective internal radiation therapy, hepatocellular carcinoma, inferior phrenic artery, radioembolization, interventional radiology, cone-beam computed tomography, lung shunt fraction, mRECIST, extrahepatic collateral supply, tumor response, coil embolization